Source comparison
Comparison: PT-141 vs Other HSDD Treatment Timelines
PT-141 (bremelanotide) MC4R agonist in CNS 45 min – 8 hours 2–4 hours post-injection Up to 72 hours Fastest-acting option for desire generation; requires subcutaneous injection; nausea in 40% during titration Flibanserin (Addyi) 5-HT1A agonist, 5-HT2A antagoni
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC4R agonist in CNS
- 45 min – 8 hours
- 2–4 hours post-injection
- Up to 72 hours
- Fastest-acting option for desire generation; requires subcutaneous injection; nausea in 40% during titration
- Flibanserin (Addyi)
- 5-HT1A agonist, 5-HT2A antagonist
- 4–8 weeks daily dosing
- Weeks 8–12 of therapy
- Requires continuous use
- Chronic dosing model; effect requires 8+ weeks to manifest; contraindicated with alcohol
- Testosterone (off-label)
- Androgen receptor activation
- 2–4 weeks (transdermal)
- Weeks 6–12
- Off-label for HSDD in women; highly variable response; requires monitoring for virilization
- Bupropion (off-label)
- NDRI. Dopamine/norepinephrine reuptake inhibition
- 1–3 weeks
- Weeks 4–6
- Primarily an antidepressant; HSDD benefit is secondary; seizure risk at high doses